GlobeStar Therapeutics Corp financial data

Location
Richland, WA
Fiscal year end
30 September
Latest financial report
10-Q - Q2 2024 - 11 Oct 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -104% % -3.4%
Return On Equity 59% % -62%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,241,105,695 shares
Common Stock, Shares, Outstanding 1,241,105,695 shares 42%
Common Stock, Value, Issued $1,241,106 USD 42%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $804,598 USD -57%
Operating Income (Loss) $804,598 USD 57%
Nonoperating Income (Expense) $82,358 USD -170%
Net Income (Loss) Attributable to Parent $886,956 USD 53%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $41 USD
Assets, Current $83,874 USD
Assets $83,874 USD
Accounts Payable, Current $434,865 USD 117%
Liabilities, Current $1,708,806 USD 34%
Liabilities $1,708,806 USD 34%
Retained Earnings (Accumulated Deficit) $21,022,748 USD -4.6%
Stockholders' Equity Attributable to Parent $1,624,932 USD -27%
Liabilities and Equity $83,874 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares, Issued 1,241,105,695 shares 42%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $41 USD
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Additional Paid in Capital $17,976,581 USD 0.32%
Interest Expense $82,358 USD 95%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares